Catharina Larsson's Group
The Medical Genetics research group was started in 1993 within the Department of Molecular Medicine and Surgery of KI. In 2013, the research group moved to the Department of Oncology-Pathology. Our laboratory is located at the Cancer Center Karolinska (CCK) within Karolinska University Hospital, Solna, and we are mainly affiliated to the Clinical Pathology/Cytology Department of the Karolinska University Hospital.
Our research aims to elucidate disease development on the molecular level focusing on certain human cancers, as well as the possibly implications for clinical practice and basic mechanistic principles. The present five research teams are focused on:
- Molecular genetic backgrounds of endocrine tumor development (Catharina Larsson)
- Small RNAs in cancer development (Weng-Onn Lui)
- Genetics of tumor predisposition and progression in breast cancer and DLBCL (Svetlana Bajalica Lagercrantz)
- Endocrine molecular pathology (Christofer Juhlin)
- Markers of therapy response and outcome in breast cancer (Barbro Linderholm)
The research aims to explain tumor initiation and malignification in endocrine organs (the parathyroid glands, thyroid, and neuroendocrine tumors of the abdomen) focusing on genetic predisposing, initiating and acquired events and their cellular effects and influence of the natural course of the disease.
The research aims to understand the role of different types of non-coding RNA e.g. miRNA in cancer development and therapy response and their relation to known alterations such as known driver mutations and viral background utilizing both in vitro and in vivo approaches.
The research aims to understand tumor development to achieve improved patient handling in clinical oncology including: Genetic predisposition in hereditary cancer syndromes with focus on breast cancer; and genetic markers for early detection and tumor spread in breast cancer.
The research aims to identify key molecular and mutational events in thyroid, adrenal and other endocrine tumors, and their clinical applications in endocrine pathology and molecular pathology for improved decisions in diagnosis, prognosis and treatment.
The research aims to identify recurrent molecular alterations identified by e.g. miRNA and proteome expression screenings in large groups of breast cancer which significantly influence the response to available oncological therapies and which may be applied to improve therapy decision making for the individual patient.
The research aims to identify peptides, tumor growth factors and receptors that are expressed by neuroendocrine tumors and could be used as tools for their diagnosis, follow up and treatment. Furthermore, we focus at the endoscopic diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors.
Zeiss Axioplan 2
Contact person: Weng-Onn Lui
Biotage PyroMark Q24
Contact person: Adam Stenman
StepOnePlus Applied Biosystems
Contact person: Satendra Kumar
RNA in situ equipment
Contact person: WEng-Onn Lui
Leica DM 2000
Contact person: Adam Stenman